CombiMatrix CorpCBMX rose 25.9 percent to $3.40 in pre-market trading after the company reported that its pre-implantation genetic screening by next generation sequencing has been granted a conditional approval from the New York State Department of Health.
Vascular Biogenics LtdVBLT rose 18 percent to $5.90 in pre-market trading after the company disclosed top-line results from its Phase 2 study of VB-111 in patients with advanced, differentiated thyroid cancer.
Thor Industries, Inc.THO rose 8.6 percent to $98.20 in pre-market trading as the company reported stronger-than-expected results for its first quarter on Monday.
Tiffany & Co.TIF shares rose 5.3 percent to $82.25 in pre-market trading after the company reported stronger-than-expected results for its third quarter on Tuesday.
Nivalis Therapeutics IncNVLS shares fell 53.6 percent to $2.90 in pre-market trading after the company disclosed results from Phase 2 clinical trial of cavosonstat for the treatment of cystic fibrosis. The company reported that the trial failed to demonstrate benefit in absolute change in percent predicted FEV1 or in sweat chloride reduction at 12 weeks.
Amicus Therapeutics, Inc.FOLD shares fell 24.9 percent to $6.25 in pre-market trading after the company reported a regulatory plan for full approval pathway for migalastat.
Shoe Carnival, Inc.SCVL fell 12.8 percent to $26.40 in pre-market trading after the company reported weak earnings for its third quarter and lowered its annual outlook.